How Cannabis Led Scientists to Discover the Endocannabinoid System
A plant molecule became the clue that revealed an entire signaling network already operating inside the human body.
From cannabis chemistry to a hidden human system
The endocannabinoid system was not found in one experiment. It emerged through decades of chemistry, pharmacology, receptor biology, and neuroscience.
CBD was isolated
Researchers isolated cannabidiol from cannabis, giving science one of its first purified plant cannabinoids to study.
CBD and THC structures were solved
Raphael Mechoulam, Yechiel Gaoni, and colleagues clarified the chemistry of CBD and delta-9 THC. Knowing THC’s structure made controlled experiments possible.
A specific brain receptor appeared
Radioligand experiments showed that cannabinoids bind to specific sites in the brain. THC was not simply disturbing cell membranes. It was interacting with a receptor.
The CB1 receptor was cloned
Scientists identified the gene encoding the brain cannabinoid receptor, allowing its distribution and function to be studied in detail.
Anandamide was discovered
Researchers isolated an endogenous molecule that activates the same receptor. The body had its own cannabinoid-like signaling chemical.
The system filled in
CB2 was cloned, 2-AG was identified as another endocannabinoid, and FAAH was characterized as an enzyme that breaks anandamide down.
Six discoveries that built the endocannabinoid system
THC received a defined molecular identity
Gaoni and Mechoulam isolated and described delta-9 THC, the principal intoxicating cannabinoid. A defined structure gave researchers a reproducible tool for investigating cannabis effects. View the original paper.
Specific cannabinoid binding sites were found in the brain
Allyn Howlett’s research team used a radiolabeled cannabinoid to demonstrate saturable, high-affinity binding in rat brain membranes. This was strong evidence for a dedicated receptor mechanism. View the study.
The cannabinoid receptor gene was cloned
Cloning the receptor now called CB1 turned a pharmacological signal into a specific protein and gene. Researchers could map where it was expressed and test how it signaled. View the study.
Anandamide showed that the receptor had a natural partner
William Devane, Lumir Hanus, Raphael Mechoulam, and colleagues isolated a lipid from pig brain that bound the cannabinoid receptor. They named it anandamide. View the Science paper.
CB2 expanded the system beyond CB1
A second cannabinoid receptor was cloned from human promyelocytic leukemia cells. Its distribution differed from CB1 and helped open research into immune and peripheral signaling. View the study.
2-AG became another endogenous cannabinoid messenger
Researchers identified 2-arachidonoylglycerol, or 2-AG, as an endogenous ligand for cannabinoid receptors. It is now recognized as a major endocannabinoid signal. View the study.
What the endocannabinoid system actually is
The ECS is a flexible signaling system, not one organ or a pool of cannabis chemicals. Its major parts work locally and are often produced on demand.
Receptors
CB1 is abundant in the nervous system. CB2 is associated more strongly with immune and peripheral tissues, although both have wider distributions than those labels suggest.
Messengers
Anandamide and 2-AG are lipids made by the body. They are called endocannabinoids because they can activate cannabinoid receptors.
Enzymes
Enzymes create and clear endocannabinoids. FAAH helps break down anandamide, while MAGL is a major route for breaking down 2-AG.
Why this scientific success story mattered
The discovery gave researchers a new framework for studying appetite, pain, memory, movement, stress responses, nausea, inflammation, and other functions. It also explained why THC can affect so many experiences at once. CB1 receptors are distributed across multiple brain networks rather than sitting in a single “high center.”
The ECS also became a drug-development target. Some cannabinoid medicines reached clinical use, while other strategies failed or produced unacceptable effects. Rimonabant, for example, showed that blocking CB1 could affect weight but also created serious psychiatric safety concerns. Discovering a system creates possibilities, not automatic treatments.
Frequently asked questions
What is the endocannabinoid system?
It is a body-wide signaling network involving cannabinoid receptors, endogenous lipid messengers such as anandamide and 2-AG, and enzymes that make and clear those messengers.
Why is it called the endocannabinoid system?
Researchers found the body’s own receptor-activating molecules after studying cannabis. “Endo” means within, so endocannabinoids are cannabinoid-like signals produced inside the body.
Who discovered the endocannabinoid system?
No single scientist discovered the whole system. Important contributors included Raphael Mechoulam, Yechiel Gaoni, Allyn Howlett, William Devane, Lumir Hanus, Tom Bonner, and many collaborators.
When was the endocannabinoid system discovered?
The central sequence unfolded from the late 1980s through the mid-1990s, including the cannabinoid receptor in 1988, CB1 cloning in 1990, anandamide in 1992, CB2 in 1993, and 2-AG in 1995.
Does the body naturally produce THC?
No. THC is a phytocannabinoid produced by cannabis. The body makes endocannabinoids such as anandamide and 2-AG, which are chemically different.
What do CB1 and CB2 receptors do?
They are cell-surface receptors that change cellular signaling when activated. CB1 has major roles in neural signaling, while CB2 is prominent in immune and peripheral biology. Their functions overlap and depend on location.
Does everyone have an endocannabinoid system?
Yes. It is a normal part of vertebrate biology and exists whether or not a person uses cannabis.
Does the ECS prove cannabis is medicine for everything?
No. A biological target does not establish that every cannabinoid product safely treats every symptom. Each medical claim needs evidence from appropriate human studies.
Research sources
Medical note: This page is educational and is not medical advice. Cannabis and cannabinoid products can cause impairment, interact with medicines, and carry different risks depending on dose, route, age, pregnancy, and health history.
Chris Garcia, Owner and CEO
September 5, 2026
How this page is prepared: Plenny uses linked research and other relevant sources for educational explanations, and product details and batch COAs where relevant. General strain, flavor, and effect descriptions are not guarantees.
Commercial transparency: Plenny sells products discussed on this website. Educational pages are not medical or legal advice, and content is not medically reviewed unless a named licensed reviewer is shown.